Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stomach Neoplasms 2Cholangiocarcinoma 2Acrocephalosyndactylia 2Urinary Bladder Neoplasms 1Upper Tract Urothelial Carcinomas 1Tumor With Alterations of the FGF-R 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioblastoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

infigratinib 1Drug Evaluation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Upper Tract Urothelial Carcinomas × infigratinib × Clear all
NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated
39 enrolled 31 charts
Genitourinary

Upper Tract Urothelial Carcinomas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡